Editorial
Back to Basics – Part 1: Are We Over Treating Ocular Hypertension and
Primary Open Angle Glaucoma Patients?
Rashid Zia, S. A. Raja, S. Aqil
Pak J Ophthalmol 2019, Vol. 35, No. 1
. . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . ..
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Poulation
explosion, availability of life saving drugs and perusal of healthier life
styles is leading to rising life expectancy worldwide. This indirectly
translates to increasing prevalence of open angle glaucoma1 worldwide
and Pakistan is no exception to these myriad factors of population increase and
related healthcare issues.
Studies have in
general shown increased glaucoma severity corelating with direct and indirect
costs associated with the progression of disease2. Hence there is a
wide spread tendency to treat suspicious optic nerve heads, mild to moderate
high intraocular pressures or even documented but non progressive glaucoma
damage without comprehensive structural, visual function, local and systemic
risk assessment. This has in turn led to plethora of adverse clinical, socioeconomic
and financial concerns triggering chain of adversities at individual and as
well as national level.
The term, “target
IOP” is widely used in clinical practice. Unfortunately, it tends to steer the management
of glaucoma patients solely dependant on reducing IOP to “acceptable” levels.
The acceptable target range(s) for IOP are often the recommendations of large
land mark clinical trials (RCT’s). This however frequently leads clinicians to
ignore the wood for the trees. There is an inclination towards treating the
pressure rather than the patient. There
is an inclination towards treating the IOP to reduce it to a magic lower value
rather than fully assess the patient/ individualised needs, incorporating a
holistic approach based on quality of life and patient choice(s). Clinicians in
their busy clinics often forget that patients are not concerned about their IOP
values, digits (decibel loss) on visual fields or colours (red disease) on OCT
scans. Rather patient is only concerned
about two things: (a) Am I going to lose vision? or/and (b) am I going to
develop disability?
To answer these
questions, clinicians are required to assess the progression of the disease and
the likelihood of disability in expected life span 3,4,5.
Assessing progression
and then the rate of progression is pivotal in taking decisions regarding
glaucoma management, for example, it is hard to justify addition of second line
of topical ocular antihypertensive drug to a regimen when patient with
intraocular pressures of 26 mm Hg on a single ocular antihypertensive drug has
not shown any evidence of structural or functional loss on trend analysis.
Similarly, a patient with documented progression on visual fields or OCT may
still not require further lowering of IOP if the rate of progression is
unlikely to cause or worsen existing disability in the life span of terminally
ill patient.
Major risk factors
for glaucoma blindness are the severity of disease at presentation and life expectancy4,6.
A 60 years old patient with bilateral moderate glaucomatous (structural and visual
functional) damage at diagnosis has a greater risk of blindness than an 85
years old with a similar amount of damage. Similarly a young patient with mild
bilateral damage is at much larger risk of disability in his life tile than an
80 years old patient with moderate unilateral disease. Thus assessing rate of
progression is an integral part of glaucoma management and the measured rate is
what should determine the target intraocular pressure and treatment intensity. Many
studies have found that progression is usually linear 77 (although variable or
non-linear progression modelling has been documented as well). Hence the goal
of initiating or intensifying the treatment is to reduce the rate of
progression to prevent disability or cause further disability. Preservation of visual
function and related quality of life should be planned at a sustainable cost. The
cost of treatment should be calculated in terms of inconvenience and side
effects as well as financial implications for the individual and society and
this requires careful evaluation marrying the ‘art and science of glaucoma’.
European Glaucoma Society
(EGS) guidelines state, “Quality of life is closely related to visual function.
Over all, patients with early to moderate glaucoma damage have good visual
function and modest reduction in quality of life (QoL), while QoL is
considerably reduced with advanced visual functional loss”8. Common
perception that no symptoms are experienced in the early stage of the disease
typically9,10 has been challenged in the recent studies, including
one large scale epidemiological study. It has been suggested that patients with
even mild unilateral visual field damage may experience reduced vision related
QoL (VRQoL) even if they are unaware that they suffer from glaucoma11.
For example, inferior hemifield damage shows a stronger correlation than
superior damage with respect to general vision, risk of falling, eye hand
coordination and mobility. While superior field is more likely to interfere
with reading and near activities12,13. This decreased quality of
life may also result in less engagement in the real world behaviour;
significantly reduced physical activity9, restriction to home and
suffering with apprehension14 and depression.
Thus when taking in
consideration the rate of progression, life expectancy, local and systemic risk
factors, patient preferences and effects on vision related quality of Life, it
is clear that there is no single “Target IOP” level that is appropriate for
every patient. The target IOP needs to be estimated separately for each eye of
every patient on every visit.
The
Hippocratic
Oath includes the
promise “Primum non nocere” i.e. as to the matter of diseases, first do no
harm. Glaucoma management is complex and requires a holistic approach without bringing
harm to patients by carefully identifying “Target IOP”
Author’s Affiliation
Rashid
Zia
Lead
Ophthalmologist New Hayesbank Ophthalmology services; Ashford Kent; Uk
Lead
Ophthalmologist Beltinge Ophthalmic Services; Kent UK
Glaucoma
Fellow East Kent HospitalsUniversityNHS Foundation Trust UK
Mohammad
S. A. Raja
Consultant
Ophthalmologist with a specialist interest in Retinal diseases and Ophthalmic
imaging
Clinical
Lead Ophthalmology James Paget University Hospital NHS Trust Norfolk UK
Clinical
Lead EADESP (East Anglian Diabetic Eye Screening Programme)
S.
Aqil
Post
graduate trainee
Financial Interest: None.
Conflict of Interest: None.
REFERENCES
1. Than YC Li X, Wong TY, et al. Global
prevalence of glaucoma and projections of glaucoma burden through 2040: a
systemic review and meta analysis. Ophthalmology, 2014; 121: 2081-2090.
2. Schmier JK, Halpren MT, Jones ML. The
economic implications of glaucoma: a literature review. Pharmacoeconomics,
2007; 25 (4): 287-308.
3. Martus P, Strous A, Budde WM, et al.
Predictive factors for progressive optic nerve damage in various types of
chronic open angle glaucoma. Am J Ophthalmology, 2005; 139 (6): 999-1009.
4. Peters D Bengtsson B, Heijl A. Factors
associated with life time risks of open angle glaucoma blindness. Acta
ophthalmologica. 2013.
5. Foresman E, Kivea T, Vest E. Life time
visual disability on open angle glaucoma and ocular hypertension. Journal of
glaucoma, 2007; 16 (3): 313-9.
6. Martus P, stroux A, Budde WM, et al.
Predictive factors for progressive optic nerve damage in various types of chronic
open angle glaucoma. Am J Ophthal. 2005; 139 (6): 999-1009.
7. Pererira ML, Kim CS, Zimmerman MB, et al.
Rate and pattern of visual field decline in primary open angle glaucoma.
Ophthalmology, 2002; 109 (12): 2232-40.
8. Terminology
and Guidelines for Glaucoma; European Glaucoma Society; 4th Edition; Chapter 3
Treatment Principles and Options, pg 133.
9. Ramulu PY, Maul E, Hochberg C, et al.
Real world assessment of physical activity in glaucoma using an accelerometer.
Ophthalmology, 2012; 119: 1155-1166.
10. Kong XM, Zhu WQ, Hong JX, Sun XH. Is
glaucoma comprehension associated with psychological disturbance and vision
related quality of life for patients with glaucoma? A cross-sectional study.
BMJ Open, 2014.
11. Peters D, Heijl A, Brenner L, Bengston B.
Visual impairment and vision-related quality of life in the early Manifest
Glaucoma trial after 20 years of follow up. Acta Ophthalmol. 2015; 93: 745-752.
12. Maruta H, Hirasawa H, Ayoma Y, et al.
Identifying areas of the visual field important for quality of life in patients
with glaucoma. Ploss One 8,e58695 10.1371/journal.pone.0058695(2013)
13. Sun Y linc C, Waisbourd M, et al. The
impact of visual field clusters on performance-based measures and
vision-related quality of life in patients with glaucoma. Am J Ophthalmol.
2016; 163: 45-52.
14. Kotecha A; O’Leary N, Melmonth D, Grant S,
Crabb DP. The functional consequences of glaucoma for eye-hand
coordination. Invest Ophthalmol Vis Sci 20. 09; 50 (1): 2003-213.